ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
02 Maio 2024 - 1:15PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world’s only
natural recombinant apoA-I, announces that it has filed with the
“Autorité des Marchés Financiers” (AMF) its Universal Registration
Document for the year ended December 31, 2023, dated April 30,
2024.
ABIONYX Pharma's Universal Registration Document for the
financial year ending December 31, 2023, includes in
particular:
- The annual financial report for 2023, consisting of the
consolidated financial statements, the annual financial statements
and the related statutory auditors' reports;
- The management report;
- The corporate governance report;
- A description of the share buyback program.
This document is available on the company's website
(www.abionyx.com) and on the AMF website (www.amf-France.org). It
is also available at the company's registered office, 33-43 avenue
Georges Pompidou - Building D, Balma, 31130.
The Universal Registration Document has also been published in
European Single Electronic Format (ESEF), with the five tables of
the consolidated financial statements (the primary financial
statements) and the appendix marked up using the XBRL markup
language.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines in diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated apoA-I
-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502757962/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024